HC Wainwright Reiterates “Neutral” Rating for Zura Bio (NASDAQ:ZURA)

HC Wainwright restated their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Monday, Benzinga reports. The firm currently has a $5.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Friday.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $4.83 on Monday. Zura Bio has a one year low of $2.00 and a one year high of $6.35. The business has a 50-day simple moving average of $3.92 and a 200-day simple moving average of $3.96.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities research analysts forecast that Zura Bio will post -0.47 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 15.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new stake in shares of Zura Bio in the second quarter valued at about $43,000. Renaissance Technologies LLC boosted its holdings in Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares in the last quarter. SG Americas Securities LLC acquired a new position in Zura Bio during the 3rd quarter worth approximately $62,000. Forefront Analytics LLC raised its stake in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after buying an additional 7,531 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.